Can pharmacologic agents slow abdominal aortic aneurysm growth?

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Vascular Biology

Background:

• Abdominal aortic aneurysm (AAA) expansion is a significant clinical concern.
• Therapeutic strategies aim to modify the underlying pathophysiology of AAA progression.
• Aortic wall inflammation plays a crucial role in AAA development and expansion.

Purpose of the Study:

• To review medical therapies that may prevent abdominal aortic aneurysm expansion.
• To explain the mechanisms by which these therapies affect aortic wall inflammation.
• To assess the current evidence supporting the use of various agents in AAA management.

Main Methods:

• Literature review of studies investigating medical therapies for AAA.
• Analysis of proposed mechanisms of action related to aortic wall inflammation.
• Evaluation of evidence from animal, observational, and clinical trials.

Main Results:

• Numerous agents including hormones, vitamins, and medications have been studied.
• Limited randomized clinical trials exist, but animal and observational data are more abundant.
• Statins, doxycycline, vitamin E, cyclooxygenase-2 inhibitors, ACE inhibitors, and ARBs show potential benefit in select individuals.

Conclusions:

• Medical therapies targeting aortic wall inflammation are being explored for AAA prevention.
• Robust clinical trial data is scarce for most proposed agents.
• Certain agents like statins and doxycycline may offer benefits for specific AAA patients.